Stifel Nicolaus Cuts Cipher Pharmaceuticals (TSE:CPH) Price Target to C$17.00

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price target decreased by Stifel Nicolaus from C$19.00 to C$17.00 in a report published on Monday,BayStreet.CA reports.

CPH has been the subject of several other reports. Stifel Canada raised shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th. Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 13th.

Cipher Pharmaceuticals Stock Down 0.7 %

Cipher Pharmaceuticals stock opened at C$12.71 on Monday. Cipher Pharmaceuticals has a 12 month low of C$5.31 and a 12 month high of C$19.69. The stock has a fifty day simple moving average of C$15.84 and a two-hundred day simple moving average of C$12.36. The company has a current ratio of 11.18, a quick ratio of 2.67 and a debt-to-equity ratio of 0.33. The firm has a market cap of C$325.25 million, a price-to-earnings ratio of 10.17 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 EPS for the quarter, missing the consensus estimate of C$0.03 by C($0.02). Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The business had revenue of C$14.15 million for the quarter, compared to analysts’ expectations of C$13.37 million. Equities analysts predict that Cipher Pharmaceuticals will post 1.2907348 EPS for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.